Advertisement GSK discontinues SRT501 development study - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

GSK discontinues SRT501 development study

GlaxoSmithKline (GSK) has discontinued the development programme of an experimental drug SRT501, following disappointing clinical trial results.

The UK drug maker acquired SRT501, a proprietary formulation of resveratrol, a substance found in grapes and red wine, from biotech company Sirtris Pharmaceuticals, as part of the company’s acquisition in 2008.

Resveratrol (3,5,4′-trihydroxy-trans-stilbene) a stilbenoid, a type of polyphenol, is believed to provide anti-cancer, anti-inflammatory, blood-sugar-lowering and other cardiovascular benefits.

Reportedly, in April this year GSK terminated the SRT501 small clinical trial in people multiple myeloma, as they developed kidney complications.

That time GSK said it would analyse the data before deciding next course of action in the clinical trial.

GSK spokeswoman said going forward, they have decided to focus efforts on more selective SIRT1 activator compounds that have no chemical relationship to SRT501.